RU2013112019A - Среда для культуры клеток, не содержащая олигопептидов - Google Patents
Среда для культуры клеток, не содержащая олигопептидов Download PDFInfo
- Publication number
- RU2013112019A RU2013112019A RU2013112019/10A RU2013112019A RU2013112019A RU 2013112019 A RU2013112019 A RU 2013112019A RU 2013112019/10 A RU2013112019/10 A RU 2013112019/10A RU 2013112019 A RU2013112019 A RU 2013112019A RU 2013112019 A RU2013112019 A RU 2013112019A
- Authority
- RU
- Russia
- Prior art keywords
- virus
- cells
- vero cells
- vero
- influenza
- Prior art date
Links
- 102000015636 Oligopeptides Human genes 0.000 title 1
- 108010038807 Oligopeptides Proteins 0.000 title 1
- 239000006143 cell culture medium Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract 16
- 210000003501 vero cell Anatomy 0.000 claims abstract 16
- 241000700605 Viruses Species 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 10
- 241000700618 Vaccinia virus Species 0.000 claims abstract 8
- 241000287828 Gallus gallus Species 0.000 claims abstract 6
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract 6
- 241000315672 SARS coronavirus Species 0.000 claims abstract 4
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims abstract 4
- 241000710886 West Nile virus Species 0.000 claims abstract 4
- 241000710772 Yellow fever virus Species 0.000 claims abstract 4
- 229940051021 yellow-fever virus Drugs 0.000 claims abstract 4
- 208000005252 hepatitis A Diseases 0.000 claims abstract 3
- 241000712891 Arenavirus Species 0.000 claims abstract 2
- 241000711573 Coronaviridae Species 0.000 claims abstract 2
- 241000709661 Enterovirus Species 0.000 claims abstract 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims abstract 2
- 241000710831 Flavivirus Species 0.000 claims abstract 2
- 241000712431 Influenza A virus Species 0.000 claims abstract 2
- 241000713196 Influenza B virus Species 0.000 claims abstract 2
- 241000713666 Lentivirus Species 0.000 claims abstract 2
- 241000709664 Picornaviridae Species 0.000 claims abstract 2
- 241000710942 Ross River virus Species 0.000 claims abstract 2
- 230000002238 attenuated effect Effects 0.000 claims abstract 2
- 238000004113 cell culture Methods 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 229920000768 polyamine Polymers 0.000 claims abstract 2
- 241000701161 unidentified adenovirus Species 0.000 claims abstract 2
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract 2
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 2
- 241001430294 unidentified retrovirus Species 0.000 claims abstract 2
- 206010019799 Hepatitis viral Diseases 0.000 abstract 1
- 230000001902 propagating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/005—Protein-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Способ получения по меньшей мере одного вируса, включающий стадии:а) получения культуры клеток;b) инфицирования клеток по меньшей мере одним вирусом;c) отбора вирус-инфицированных клеток; и(d) размножения по меньшей мере одного вируса в клетках в среде, содержащей по меньшей мере 0,5 мг/л полиамина.2. Способ по п. 1, в котором среда представляет собой среду, не содержащую олигопептидов, по п. 1.3. Способ по п. 1, в котором вирус выбран из группы, состоящей из поксвирусов, коронавирусов, ортомиксовирусов, парамиксовирусов, ретровирусов, тогавирусов, флавивирусов, энтеровирусов, пикорнавирусов, аренавирусов, вирусов герпеса и аденовирусов.4. Способ по п. 1, в котором вирус выбран из группы, состоящей из вируса коровьей оспы, вируса SARS, вируса гриппа А, вируса гриппа В, лентивируса, вируса Росс-Ривер, западно-нильского вируса, вируса желтой лихорадки, вируса FSME и вируса гепатита А.5. Способ по п. 1, в котором клетки представляют собой клетки Vero или клетки куриного эмбриона.6. Способ по п. 1, в котором комбинация клетка/вирус выбрана из группы, состоящей из клеток Vero/ослабленный вирус коровьей оспы, клеток Vero/вирус коровьей оспы, клеток Vero/гепатит А, клеток Vero/вирус гриппа, клеток Vero/западно-нильский вирус, клеток Vero/вирус SARS, клеток Vero/вирус желтой лихорадки, клеток куриного эмбриона/вирус FSME и клеток куриного эмбриона/модифицированный вирус коровьей оспы Ankara (MVA).
Claims (6)
1. Способ получения по меньшей мере одного вируса, включающий стадии:
а) получения культуры клеток;
b) инфицирования клеток по меньшей мере одним вирусом;
c) отбора вирус-инфицированных клеток; и
(d) размножения по меньшей мере одного вируса в клетках в среде, содержащей по меньшей мере 0,5 мг/л полиамина.
2. Способ по п. 1, в котором среда представляет собой среду, не содержащую олигопептидов, по п. 1.
3. Способ по п. 1, в котором вирус выбран из группы, состоящей из поксвирусов, коронавирусов, ортомиксовирусов, парамиксовирусов, ретровирусов, тогавирусов, флавивирусов, энтеровирусов, пикорнавирусов, аренавирусов, вирусов герпеса и аденовирусов.
4. Способ по п. 1, в котором вирус выбран из группы, состоящей из вируса коровьей оспы, вируса SARS, вируса гриппа А, вируса гриппа В, лентивируса, вируса Росс-Ривер, западно-нильского вируса, вируса желтой лихорадки, вируса FSME и вируса гепатита А.
5. Способ по п. 1, в котором клетки представляют собой клетки Vero или клетки куриного эмбриона.
6. Способ по п. 1, в котором комбинация клетка/вирус выбрана из группы, состоящей из клеток Vero/ослабленный вирус коровьей оспы, клеток Vero/вирус коровьей оспы, клеток Vero/гепатит А, клеток Vero/вирус гриппа, клеток Vero/западно-нильский вирус, клеток Vero/вирус SARS, клеток Vero/вирус желтой лихорадки, клеток куриного эмбриона/вирус FSME и клеток куриного эмбриона/модифицированный вирус коровьей оспы Ankara (MVA).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75641906P | 2006-01-04 | 2006-01-04 | |
US60/756,419 | 2006-01-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008131953/10A Division RU2486236C2 (ru) | 2006-01-04 | 2007-01-03 | Способ экспрессии белка |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017144220A Division RU2758802C2 (ru) | 2006-01-04 | 2017-12-18 | Среда для культуры клеток, не содержащая олигопептидов |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2013112019A true RU2013112019A (ru) | 2014-09-27 |
RU2642269C2 RU2642269C2 (ru) | 2018-01-24 |
RU2642269C9 RU2642269C9 (ru) | 2018-10-31 |
Family
ID=37942126
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008131953/10A RU2486236C2 (ru) | 2006-01-04 | 2007-01-03 | Способ экспрессии белка |
RU2013112019A RU2642269C9 (ru) | 2006-01-04 | 2013-03-18 | Среда для культуры клеток, не содержащая олигопептидов |
RU2017144220A RU2758802C2 (ru) | 2006-01-04 | 2017-12-18 | Среда для культуры клеток, не содержащая олигопептидов |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008131953/10A RU2486236C2 (ru) | 2006-01-04 | 2007-01-03 | Способ экспрессии белка |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017144220A RU2758802C2 (ru) | 2006-01-04 | 2017-12-18 | Среда для культуры клеток, не содержащая олигопептидов |
Country Status (18)
Country | Link |
---|---|
US (4) | US20070212770A1 (ru) |
EP (4) | EP3653699A1 (ru) |
JP (6) | JP5259418B2 (ru) |
KR (2) | KR101422435B1 (ru) |
CN (2) | CN102643777A (ru) |
AU (1) | AU2007204044B2 (ru) |
CA (1) | CA2633306A1 (ru) |
CY (1) | CY1119046T1 (ru) |
DK (3) | DK3121266T3 (ru) |
ES (3) | ES2474573T3 (ru) |
HK (1) | HK1177950A1 (ru) |
HU (1) | HUE032744T2 (ru) |
LT (1) | LT1974014T (ru) |
PL (3) | PL1974014T3 (ru) |
PT (3) | PT1974014T (ru) |
RU (3) | RU2486236C2 (ru) |
SI (1) | SI2522717T1 (ru) |
WO (1) | WO2007077217A2 (ru) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
WO2009086309A2 (en) | 2007-12-27 | 2009-07-09 | Baxter International Inc. | Cell culture processes |
SG10201805749QA (en) * | 2007-12-31 | 2018-08-30 | Baxalta Inc | Substantially animal protein-free recombinant furin and methods for producing same |
EP2250251B1 (en) | 2008-01-09 | 2017-11-22 | Sartorius Stedim Cellca GmbH | Improved culture media additive and process for using it |
CA2715719C (en) * | 2008-02-25 | 2019-08-06 | Baxter International Inc. | Method for producing continuous cell lines |
JP5719301B2 (ja) * | 2008-11-12 | 2015-05-13 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血清不含インスリン不含で第vii因子を産生する方法 |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
JP5451884B2 (ja) * | 2009-07-31 | 2014-03-26 | バクスター・インターナショナル・インコーポレイテッド | Adamtsタンパク質発現のための細胞培養培地 |
ES2579906T3 (es) | 2009-09-21 | 2016-08-17 | Baxalta GmbH | Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas |
EP3599276A1 (en) | 2010-04-26 | 2020-01-29 | Novartis AG | Improved cell culture medium |
ES2761692T5 (es) | 2010-07-08 | 2023-07-05 | Takeda Pharmaceuticals Co | Método de producción de vWF recombinante de alto peso molecular en cultivo celular |
CA2810734A1 (en) | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
CN103298482B (zh) | 2010-10-27 | 2015-08-19 | 巴克斯特国际公司 | 用于免疫耐受性诱导和免疫诊断的fviii肽 |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
CN108210889A (zh) | 2011-06-10 | 2018-06-29 | 百深有限责任公司 | 通过施用重组vwf治疗凝血疾病 |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
JP2015531244A (ja) | 2012-10-15 | 2015-11-02 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | タンパク質を製造するための哺乳動物細胞培養方法 |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
KR101641655B1 (ko) * | 2014-01-08 | 2016-07-21 | 서울대학교산학협력단 | 스퍼미딘 또는 스퍼민을 이용함으로써 생육 저해제에 대한 내성이 증진된 효모의 배양방법 |
EP3271324B1 (en) * | 2015-03-17 | 2019-09-04 | DSM IP Assets B.V. | Process for the preparation of diaminobutane |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
DK3383894T3 (da) | 2015-12-02 | 2020-06-02 | CSL Behring Lengnau AG | Forbedrede medier til eksprimering af rekombinante vitamin k-afhængige proteiner |
CN106635953B (zh) * | 2016-12-13 | 2021-02-19 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
KR102659791B1 (ko) * | 2017-07-06 | 2024-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
EP3648788B1 (en) | 2017-07-07 | 2024-05-22 | Takeda Pharmaceutical Company Limited | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf |
CN111565741A (zh) | 2017-07-07 | 2020-08-21 | 百深公司 | 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者 |
SG11202009213TA (en) | 2018-03-21 | 2020-10-29 | Baxalta Inc | Separation of vwf and vwf propeptide by chromatographic methods |
EP3781941A1 (en) | 2018-04-20 | 2021-02-24 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for produring anti-tnf antibody compositions |
CN108872758B (zh) * | 2018-05-10 | 2019-06-28 | 江苏大学 | 一种电子元器件寿命检测装置 |
BR112021008879A2 (pt) | 2018-11-13 | 2021-10-26 | Janssen Biotech, Inc. | Controle de oligometais durante a produção de anticorpos anti-cd38 |
EP3917557A1 (en) | 2019-02-01 | 2021-12-08 | Takeda Pharmaceutical Company Limited | Methods of prophylactic treatment using recombinant vwf (rvwf) |
EP3938384A4 (en) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | METHODS OF MANUFACTURING FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS |
WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
EP3947632A1 (en) | 2019-04-01 | 2022-02-09 | The Automation Partnership (Cambridge) Ltd. | Operation process for a cell cultivation system |
EP4028046B1 (en) | 2019-09-11 | 2024-02-14 | Takeda Pharmaceutical Company Limited | Methods of treatment related to complexes of von willebrand factor and complement c1q |
WO2021090888A1 (ja) | 2019-11-05 | 2021-05-14 | 味の素株式会社 | タンパク質の製造方法 |
BR112021025769A2 (pt) | 2019-12-06 | 2022-04-12 | Regeneron Pharma | Composições de proteína anti-vegf e métodos para a produção das mesmas |
MX2022009492A (es) | 2020-02-04 | 2022-11-09 | Takeda Pharmaceuticals Co | Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante. |
EP4127158A2 (en) | 2020-04-02 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
CN113151183A (zh) * | 2021-04-21 | 2021-07-23 | 赵峻岭 | 一种促进蛋白表达的培养基添加物及其应用 |
EP4367137A1 (en) | 2021-07-09 | 2024-05-15 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-IL12/IL23 antibody compositions |
US20230332201A1 (en) | 2022-03-02 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Cell culture methods for antibody production |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT165999B (de) | 1947-06-26 | 1950-05-25 | Delle Atel Const Electr | Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom |
US4443540A (en) * | 1980-05-09 | 1984-04-17 | University Of Illinois Foundation | Protein hydrolysis |
DK207980A (da) * | 1980-05-13 | 1981-11-14 | Novo Industri As | Fremgangsmaade til fremstilling af et skumnings- eller emulgeringsmiddel paa sojaproteinbasis |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
FR2543158B1 (fr) | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu |
US4767704A (en) * | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
IL74909A (en) | 1984-04-20 | 1992-01-15 | Genentech Inc | Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein |
ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
US4978616A (en) * | 1985-02-28 | 1990-12-18 | Verax Corporation | Fluidized cell cultivation process |
JP2520681B2 (ja) | 1986-08-04 | 1996-07-31 | ザ ユニバーシティ オブ ニュー サウス ウェールズ | 生合成のヒトの成長ホルモン製品 |
US5045468A (en) | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
KR890701731A (ko) | 1987-06-30 | 1989-12-21 | 로버트 디. 웨이스트 | 칼리크레인의 제조방법 |
JP2507882B2 (ja) | 1988-02-17 | 1996-06-19 | 工業技術院長 | 外部増殖因子非依存性増殖良好細胞株の製造法 |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5573937A (en) * | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
ATE145235T1 (de) | 1990-01-22 | 1996-11-15 | Us Health | Co-unabhängiges nährmedium zur haltung und vermehrung von zellen |
JP2844484B2 (ja) | 1990-02-22 | 1999-01-06 | 味の素株式会社 | 組換え蛋白質の生産方法 |
JP2859679B2 (ja) | 1990-03-01 | 1999-02-17 | 協和醗酵工業株式会社 | 新規細胞株 |
JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
US5378612A (en) * | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
CA2053433C (en) | 1990-10-19 | 1997-03-25 | Michael Joseph Garvey | Detergent compositions |
JPH04228066A (ja) | 1990-10-23 | 1992-08-18 | Rikagaku Kenkyusho | 外来遺伝子発現用培養細胞 |
EP0531562A1 (de) * | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Kultivierung von Säugetierzellen |
CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
JPH05123178A (ja) | 1991-11-01 | 1993-05-21 | Ajinomoto Co Inc | L−フエニルアラニンの製造法 |
AU7895898A (en) | 1993-04-26 | 1998-10-08 | Hans Wolf | Mammal cell lines and method of obtaining glycoproteins |
DE4313620A1 (de) | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamsterzellinien und Verfahren zur Glykoproteingewinnung |
GB9311132D0 (en) * | 1993-05-28 | 1993-07-14 | Eisai London Res Lab Ltd | Control of cell death |
US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
JP2766165B2 (ja) | 1993-08-02 | 1998-06-18 | 株式会社バイオポリマー・リサーチ | バクテリアセルロースの製造方法 |
US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
EP0653487A1 (de) | 1993-11-07 | 1995-05-17 | Ferruccio Dr. Messi | Serum- und proteinfrei wachsende Zellen |
US5719050A (en) * | 1993-12-24 | 1998-02-17 | Eiken Chemical Co., Ltd. | Animal cell culturing media containing N-acetyl-L-glutamic acid |
US5498599A (en) * | 1994-01-21 | 1996-03-12 | Amgen Inc. | Methods for stimulating platelet production |
EP0666312A1 (en) * | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
WO1996007730A2 (de) | 1994-09-09 | 1996-03-14 | Renner Wolfgang A | Chemisches verfahren zur förderung der proliferation von tierischen zellen |
JP3158157B2 (ja) | 1994-11-10 | 2001-04-23 | バクスター・アクチエンゲゼルシャフト | 無蛋白培養における生物製剤の製造法 |
AT403167B (de) | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
JPH10511082A (ja) | 1994-12-16 | 1998-10-27 | ノバルティス・アクチエンゲゼルシャフト | 組換え分泌成分の製造 |
US5741705A (en) * | 1995-02-23 | 1998-04-21 | Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. | Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides |
EP0811056B1 (en) | 1995-02-23 | 2000-05-31 | Quest International B.V. | Peptides for tissue and cell culture media |
WO1996040866A1 (en) | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
EP2218775B1 (en) | 1996-08-30 | 2015-01-28 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
AU4081997A (en) | 1996-08-30 | 1998-03-19 | University Of North Carolina At Chapel Hill, The | Immortalized human hepatic cell line |
EP1983044B1 (en) | 1996-10-10 | 2016-08-10 | Life Technologies Corporation | Animal cell culture media comprising plant-derived nutrients |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
ES2293681T3 (es) | 1997-05-28 | 2008-03-16 | Novartis Vaccines And Diagnostics S.R.L. | Medio de cultivo con extracto de soja como fuente de aminoacidos pero sin complejos proteinicos de origen animal. |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
ES2273434T3 (es) | 1997-07-23 | 2007-05-01 | Roche Diagnostics Gmbh | Obtencion de la eritropoyetina mediante activacion genica endogena. |
AU731857B2 (en) | 1997-11-20 | 2001-04-05 | Weyerhaeuser Company | Nutritive media and manufactured seeds comprising same |
AU2455199A (en) | 1998-01-12 | 1999-07-26 | Betagene, Inc. | Compositions and methods for regulated secretion from neuroendocrine cell lines |
FR2775983B1 (fr) | 1998-03-13 | 2000-11-10 | Pasteur Merieux Serums Vacc | Milieu et procede de propagation et de multiplication virales |
WO1999057246A1 (en) | 1998-05-01 | 1999-11-11 | Life Technologies, Inc. | Animal cell culture media comprising non-animal or plant-derived nutrients |
US6537782B1 (en) * | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
JP4266055B2 (ja) | 1999-03-04 | 2009-05-20 | 雪印乳業株式会社 | ポリアミン組成物の製造法 |
AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
CA2381173A1 (en) | 1999-08-05 | 2001-02-15 | Baxter Aktiengesellschaft | Recombinant stable cell clone, its production and use thereof |
WO2001014529A1 (en) | 1999-08-25 | 2001-03-01 | Immunex Corporation | Compositions and methods for improved cell culture |
US6596526B1 (en) * | 2000-06-09 | 2003-07-22 | Baxter Aktiengesellschaft | Furin polypeptides with improved characteristics |
ATE434035T1 (de) | 2000-09-25 | 2009-07-15 | Polymun Scient Immunbio Forsch | Lebender influenza impfstoff und verfahren zu seiner herstellung |
EP1208966A1 (en) | 2000-11-27 | 2002-05-29 | Cheng-Kun Liao | Manufacturing process of patio tabletop glass with broken protection |
DE10059175A1 (de) | 2000-11-29 | 2002-06-20 | Siemens Ag | Verfahren und Vorrichtung zur Anrufumleitung mittels eines Stellvertreters in einem Kommunikationssystem |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
US6734289B2 (en) * | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
WO2002101019A2 (en) | 2001-06-13 | 2002-12-19 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
US7037658B2 (en) * | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
HUP0402158A2 (hu) | 2001-10-02 | 2005-01-28 | Novo Nordisk Health Care Ag | Rekombináns fehérjék előállítási eljárása eukarióta sejtekben |
US20030104527A1 (en) * | 2001-12-03 | 2003-06-05 | National Research Council Of Canada | Methylotrophic bacterium for the production of recombinant proteins and other products |
DE10161412A1 (de) | 2001-12-13 | 2003-07-03 | Aventis Pharma Gmbh | Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität |
ES2398706T3 (es) * | 2002-07-09 | 2013-03-21 | Baxter International Inc. | Medio exento de proteínas animales para el cultivo de células |
FR2846005B1 (fr) | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | Composition pour milieu biologique comprenant de l'erythorbate de sodium |
FR2846004B1 (fr) | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol |
DE10333675A1 (de) | 2003-07-24 | 2005-03-03 | Aventis Pharma Deutschland Gmbh | Perfusionsverfahren für die Produktion von Erythropoietin |
WO2005035748A1 (en) | 2003-10-10 | 2005-04-21 | Novo Nordisk Health Care Ag | Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
WO2006050050A2 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
-
2007
- 2007-01-03 ES ES12160789.9T patent/ES2474573T3/es active Active
- 2007-01-03 JP JP2008548995A patent/JP5259418B2/ja active Active
- 2007-01-03 ES ES07702574.0T patent/ES2629304T3/es active Active
- 2007-01-03 US US11/649,694 patent/US20070212770A1/en not_active Abandoned
- 2007-01-03 PL PL07702574T patent/PL1974014T3/pl unknown
- 2007-01-03 RU RU2008131953/10A patent/RU2486236C2/ru active
- 2007-01-03 DK DK16183987.3T patent/DK3121266T3/da active
- 2007-01-03 HU HUE07702574A patent/HUE032744T2/en unknown
- 2007-01-03 PT PT77025740T patent/PT1974014T/pt unknown
- 2007-01-03 CN CN2012100603866A patent/CN102643777A/zh active Pending
- 2007-01-03 ES ES16183987T patent/ES2790887T3/es active Active
- 2007-01-03 PL PL12160789T patent/PL2522717T3/pl unknown
- 2007-01-03 DK DK12160789T patent/DK2522717T3/da active
- 2007-01-03 EP EP19214402.0A patent/EP3653699A1/en active Pending
- 2007-01-03 LT LTEP07702574.0T patent/LT1974014T/lt unknown
- 2007-01-03 SI SI200731439T patent/SI2522717T1/sl unknown
- 2007-01-03 WO PCT/EP2007/000027 patent/WO2007077217A2/en active Application Filing
- 2007-01-03 KR KR1020137022322A patent/KR101422435B1/ko active IP Right Grant
- 2007-01-03 DK DK07702574.0T patent/DK1974014T3/en active
- 2007-01-03 CA CA002633306A patent/CA2633306A1/en not_active Abandoned
- 2007-01-03 KR KR1020087018889A patent/KR101423344B1/ko active IP Right Grant
- 2007-01-03 EP EP07702574.0A patent/EP1974014B1/en not_active Revoked
- 2007-01-03 PL PL16183987T patent/PL3121266T3/pl unknown
- 2007-01-03 AU AU2007204044A patent/AU2007204044B2/en active Active
- 2007-01-03 PT PT161839873T patent/PT3121266T/pt unknown
- 2007-01-03 EP EP16183987.3A patent/EP3121266B8/en not_active Revoked
- 2007-01-03 PT PT121607899T patent/PT2522717E/pt unknown
- 2007-01-03 EP EP20120160789 patent/EP2522717B1/en not_active Revoked
- 2007-01-03 CN CNA2007800017871A patent/CN101360820A/zh active Pending
-
2011
- 2011-02-25 US US13/035,696 patent/US20110151512A1/en not_active Abandoned
-
2013
- 2013-03-01 JP JP2013040650A patent/JP2013106616A/ja not_active Withdrawn
- 2013-03-18 RU RU2013112019A patent/RU2642269C9/ru active
- 2013-05-13 HK HK13105678A patent/HK1177950A1/xx unknown
-
2014
- 2014-10-15 JP JP2014210677A patent/JP2015006209A/ja not_active Withdrawn
-
2015
- 2015-11-16 US US14/942,771 patent/US9758568B2/en active Active
-
2016
- 2016-12-28 JP JP2016254914A patent/JP6567490B2/ja active Active
-
2017
- 2017-06-07 CY CY20171100596T patent/CY1119046T1/el unknown
- 2017-08-07 US US15/670,217 patent/US10696731B2/en active Active
- 2017-12-18 RU RU2017144220A patent/RU2758802C2/ru not_active Application Discontinuation
-
2018
- 2018-01-09 JP JP2018001241A patent/JP2018075032A/ja not_active Withdrawn
-
2019
- 2019-11-29 JP JP2019216735A patent/JP7134157B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013112019A (ru) | Среда для культуры клеток, не содержащая олигопептидов | |
Karim et al. | Propidium monoazide reverse transcriptase PCR and RT-qPCR for detecting infectious enterovirus and norovirus | |
Ruiz et al. | Role of Ca2+ in the replication and pathogenesis of rotavirus and other viral infections | |
Bowie et al. | Viral evasion and subversion of pattern-recognition receptor signalling | |
Rawlinson et al. | The nucleolar interface of RNA viruses | |
DK2261377T3 (da) | Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner | |
Morikawa et al. | An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection | |
CY1114598T1 (el) | Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου | |
AR053913A1 (es) | Cepa atenuada de dengue serotipo 1 | |
RU2013103535A (ru) | Иммортализованная клеточная линия птиц | |
CO6141481A2 (es) | Flavirus seudoinfecciosos y usos de los mismos | |
JP2010138205A5 (ru) | ||
NO20080358L (no) | Fremgangsmater og sammensetninger for a fremstille negative-sense virus RNA i hundedyrceller | |
Marennikova et al. | Poxviruses isolated from clinically ill and asymptomatically infected monkeys and a chimpanzee | |
Pratelli et al. | Role of the lipid rafts in the life cycle of canine coronavirus | |
NO20082743L (no) | Kimaere virus som fremviser ikke-native overflateproteiner samt anvendelse derav | |
EA201001202A1 (ru) | Атенуированные онколитические парамиксовирусы, кодирующие птичьи цитокины | |
JP2008522618A5 (ru) | ||
Ammayappan et al. | Identification of sequence changes responsible for the attenuation of avian infectious bronchitis virus strain Arkansas DPI | |
BRPI0414810A (pt) | composições baseadas no vìrus seneca valley e métodos para tratar doença | |
ATE302268T1 (de) | Methode zur gewinnung und reinigung von poxviren aus infizierten zellen | |
Yoshii et al. | A critical determinant of neurological disease associated with highly pathogenic tick-borne flavivirus in mice | |
HRP20191324T1 (hr) | Spojevi, metode i načini uporabe za induciranje razvoja virusa | |
ATE399210T1 (de) | Knockout-mutante von vaccinia-virus und verwendung davon | |
NO20062967L (no) | Mutert virus, fremgangsmate for fremstilling, og anvendelse av samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant | ||
TH4A | Reissue of patent specification | ||
TK49 | Information related to patent modified |
Free format text: CORRECTION TO CHAPTER -FG4A- IN JOURNAL 3-2018 FOR INID CODE(S) (54) |
|
TH4A | Reissue of patent specification | ||
TK49 | Information related to patent modified |
Free format text: CORRECTION TO CHAPTER -FG4A- IN JOURNAL 3-2018 FOR INID CODE(S) (73) |
|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20211028 |